Condition
Ethmoid Sinusitis
Total Trials
3
Recruiting
0
Active
0
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
3 treatments under study, led by Sinopsys Lacrimal Stent
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
Termination Rate
0.0%
0 terminated out of 3 trials
Success Rate
100.0%
+13.4% vs benchmark
Late-Stage Pipeline
33%
1 trials in Phase 3/4
Results Transparency
33%
1 of 3 completed with results
Key Signals
1 with results100% success
Data Visualizations
Phase Distribution
3Total
Not Applicable (1)
Early Phase 1 (1)
Phase 4 (1)
Trial Status
Completed3
Trial Success Rate
100.0%
Benchmark: 86.6%
Based on 3 completed trials
Clinical Trials (3)
Showing 3 of 3 trials
NCT03304951Not ApplicableCompletedPrimary
Sinopsys® Lacrimal Stent Indicated for Sinus Irrigation
NCT02297243Early Phase 1CompletedPrimary
Sinopsys Lacrimal Stent Indicated for Sinus Irrigation
NCT00554190Phase 4CompletedPrimary
Study to Evaluate Safety and Effectiveness of AdvaCoat Sinus Gel
Showing all 3 trials
Research Network
Common Treatments
- Sinopsys Lacrimal Stent2
- Advacoat Sinus Gel1
- Merogel Injectable1
Active Sponsors
- Sinopsys Surgical2
- Carbylan Therapeutics, Inc.1
Top Investigators
Sinopsys Surgical Inc.
Charles University, Pilsen Czech Republic
University of California, San Francisco, Medical Center
Related Conditions
- Rhinosinusitis1